FLT3 and acute myeloid leukemia: In the phase 3 QuANTUM-R study (NCT02039726), patients with relapsed/refractory FLT3-ITD–positive AML were randomized to standard chemotherapy or single-agent quizartinib administered at 60 mg/day with a 30-mg/day lead-in (or 30 mg/day with a 20-mg/day lead-in for patients taking a strong CYP3A inhibitor).